CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors combined with CD19 positive feeder T cells treatment for CD19+ acute lymphoblastic leukemia patients in remission .
Epistemonikos ID: 9815e34b465b75dbaee33571f3a16d18e41aa5c8
First added on: May 13, 2024